98 related articles for article (PubMed ID: 17389763)
1. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera.
Dupont S; Massé A; James C; Teyssandier I; Lécluse Y; Larbret F; Ugo V; Saulnier P; Koscielny S; Le Couédic JP; Casadevall N; Vainchenker W; Delhommeau F
Blood; 2007 Aug; 110(3):1013-21. PubMed ID: 17389763
[TBL] [Abstract][Full Text] [Related]
2. Novel germline JAK2
Song J; Lanikova L; Kim SJ; Papadopoulos N; Meznarich J; Constantinescu SN; Parsegov B; Prchal JF; Prchal JT
Am J Hematol; 2024 Jul; 99(7):1220-1229. PubMed ID: 38629639
[TBL] [Abstract][Full Text] [Related]
3. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.
Levine RL; Belisle C; Wadleigh M; Zahrieh D; Lee S; Chagnon P; Gilliland DG; Busque L
Blood; 2006 May; 107(10):4139-41. PubMed ID: 16434490
[TBL] [Abstract][Full Text] [Related]
4. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.
Chen E; Beer PA; Godfrey AL; Ortmann CA; Li J; Costa-Pereira AP; Ingle CE; Dermitzakis ET; Campbell PJ; Green AR
Cancer Cell; 2010 Nov; 18(5):524-35. PubMed ID: 21074499
[TBL] [Abstract][Full Text] [Related]
5. Identification of an acquired JAK2 mutation in polycythemia vera.
Zhao R; Xing S; Li Z; Fu X; Li Q; Krantz SB; Zhao ZJ
J Biol Chem; 2005 Jun; 280(24):22788-92. PubMed ID: 15863514
[TBL] [Abstract][Full Text] [Related]
6. Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.
King KY; Matatall KA; Shen CC; Goodell MA; Swierczek SI; Prchal JT
Exp Hematol; 2015 Oct; 43(10):912-918.e2. PubMed ID: 26072330
[TBL] [Abstract][Full Text] [Related]
7. The utility of testing erythropoietin level in polycythemia diagnosis.
Ismail A; Abdalla E; Aqel A; Fadul A; Ahmed A; Alsayed A; Musa M; Yassin MA
Hematology; 2023 Dec; 28(1):2269510. PubMed ID: 37843428
[TBL] [Abstract][Full Text] [Related]
8. Iron homeostasis governs erythroid phenotype in polycythemia vera.
Bennett C; Jackson VE; Pettikiriarachchi A; Hayman T; Schaeper U; Moir-Meyer G; Fielding K; Ataide R; Clucas D; Baldi A; Garnham AL; Li-Wai-Suen CSN; Loughran SJ; Baxter EJ; Green AR; Alexander WS; Bahlo M; Burbury K; Ng AP; Pasricha SR
Blood; 2023 Jun; 141(26):3199-3214. PubMed ID: 36928379
[TBL] [Abstract][Full Text] [Related]
9. At last: erythropoietin as a single glycoform.
Wang P; Dong S; Brailsford JA; Iyer K; Townsend SD; Zhang Q; Hendrickson RC; Shieh J; Moore MA; Danishefsky SJ
Angew Chem Int Ed Engl; 2012 Nov; 51(46):11576-84. PubMed ID: 23012228
[No Abstract] [Full Text] [Related]
10. Impact of Molecular Biology in Diagnosis, Prognosis, and Therapeutic Management of
Abbou N; Piazzola P; Gabert J; Ernest V; Arcani R; Couderc AL; Tichadou A; Roche P; Farnault L; Colle J; Ouafik L; Morange P; Costello R; Venton G
Cells; 2022 Dec; 12(1):. PubMed ID: 36611899
[No Abstract] [Full Text] [Related]
11. Inferring the initiation and development of myeloproliferative neoplasms.
Hermange G; Rakotonirainy A; Bentriou M; Tisserand A; El-Khoury M; Girodon F; Marzac C; Vainchenker W; Plo I; Cournède PH
Proc Natl Acad Sci U S A; 2022 Sep; 119(37):e2120374119. PubMed ID: 36083966
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in
Wang JC; Sun L
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628647
[TBL] [Abstract][Full Text] [Related]
13. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract][Full Text] [Related]
14. MTAP-related increased erythroblast proliferation as a mechanism of polycythaemia vera.
Tipgomut C; Khuhapinant A; Wilson MC; Poldee S; Heesom KJ; Metheetrairut C; Sripichai O; Mitrpant C; Frayne J; Trakarnsanga K
Sci Rep; 2021 Nov; 11(1):22483. PubMed ID: 34795367
[TBL] [Abstract][Full Text] [Related]
15. The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.
Spivak JL; Moliterno AR
Front Oncol; 2021; 11():641613. PubMed ID: 33777803
[TBL] [Abstract][Full Text] [Related]
16. Frequency of Zygosity in Jak-2 Positive Patients with Polycythemia Vera-Pakistan's Perspective.
Shah SZ; Raza N; Nasir MI; Zaidi SMH
Asian Pac J Cancer Prev; 2021 Feb; 22(2):559-564. PubMed ID: 33639674
[TBL] [Abstract][Full Text] [Related]
17. Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms.
Kjær L
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32731609
[TBL] [Abstract][Full Text] [Related]
18. Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms.
El-Khoury M; Cabagnols X; Mosca M; Vertenoeil G; Marzac C; Favale F; Bluteau O; Lorre F; Tisserand A; Rabadan Moraes G; Ugo V; Ianotto JC; Rey J; Solary E; Roy L; Rameau P; Debili N; Pasquier F; Casadevall N; Marty C; Constantinescu SN; Raslova H; Vainchenker W; Plo I
Oncogene; 2020 Jul; 39(31):5323-5337. PubMed ID: 32572159
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.
Spivak JL; Merchant A; Williams DM; Rogers O; Zhao W; Duffield A; Resar LS; Moliterno AR; Zhao ZJ
PLoS One; 2020; 15(6):e0232801. PubMed ID: 32479500
[TBL] [Abstract][Full Text] [Related]
20. Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation.
Perner F; Perner C; Ernst T; Heidel FH
Cells; 2019 Aug; 8(8):. PubMed ID: 31398915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
